Here are the 424B prospectus supplements from BrenX Ltd. (BRNX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BRNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BRNX filings page.
BRENX Ltd. may offer and sell ordinary shares with an aggregate offering price of up to $2,886,058 from time to time through A.G.P. in an “at the market offering.” With BRENX’s written authorization, A.G.P. may also make negotiated sales at prevailing market prices or prices related to them. A.G.P. receives a commission equal to 3.0% of gross sales price per share; net proceeds from sales are paid to BRENX.
BRENX intends to use net proceeds for general corporate purposes, working capital, research and development, capital expenditures, commercial project development, strategic investments, other business opportunities, and repayment or refinancing of existing or future indebtedness. Management retains broad discretion over their application. Sales amounts and prices may vary with market conditions and placement instructions; the prospectus cites a last reported sale price of $1.32 per share on October 13, 2026 as the basis for its offering illustration.
In a separate stated scenario, BRENX assumes sales of 2,186,408 shares, equal to approximately 52.9% of shares outstanding after those sales. BRENX stated that 1,946,972 Ordinary Shares were outstanding as of October 13, 2026. The auditor’s report on the company’s 2025 financial statements contains an explanatory paragraph relating to its ability to continue as a going concern.